Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 160
Filter
1.
Endoscopic Surgery ; 28(4):5-11, 2022.
Article in Russian | Scopus | ID: covidwho-2025839

ABSTRACT

Objective. The aim of the work was to analyze the results and treatment of acute appendicitis (AA) in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19. Material and methods. From March 16, 2020 to October 31, 2021, 139 patients with suspected AA were tread. In 104 patients (62 men and 42 women) the diagnosis of AA was confirmed. Inclusion criteria were: AA, a positive PCR (polymerase chain re-action) result for COVID-19, or a characteristic picture of viral pneumonia for COVID-19 based on computed tomography (CT). To clarify the diagnosis of acute appendicitis, all patients underwent CT scan of the abdominal organs. Results. When evaluating the symptoms of AA in patients with COVID-19, no specific signs were identified. The systematic inflammatory response could be due to both surgical disease and viral infection, making it difficult to interpret the chang-es. But, in 88 patients (84.61%) in the blood test was leukocytosis from 11.81 to 34.83·109/l, which is uncommon for patients with COVID-19 at the onset of the disease. The average time from the onset of clinical manifestations of AA to the operation was 57±14 hours. 139 diagnostic laparoscopies were performed. The diagnosis of AA was confirmed in 104 patients. 102 patients underwent laparoscopic appendectomy with pelvic drainage. One patient had laparotomy, appendectomy, intestinal intubation. One patient had laparoscopic resection of Meckel’s diverticulum plus appendectomy. A positive PCR result for SARS-CoV-2 effu-sion from the abdominal cavity was confirmed in 45 out of 75 patients (60%). According to the results of a pathomorphological study, 89 (85.58%) patients had phlegmonous appendicitis, 8 (7.69%) had gangrenous appendicitis, and 7 (6.73%) had gangre-nous-perforated appendicitis. Mortality was 0.96% (1 patient). Conclusion. Diagnostic problems of AA in patients with COVID-19 are associated with difficulties in interpreting local symptoms and systemic inflammatory response. Laparoscopy is the leading diagnostic method for suspected AA, including patients with COVID-19. In the absence of severe pneumonia, laparoscopic appendectomy is possible in most patients. All operations should be carried out in accordance with anti-epidemic measures. The clinical significance of detecting SARS-CoV-2 in the abdominal cavity needs further evaluation. The prognosis for patients is determined to a greater extent by the course of COVID-19. The tactics of treatment of patients with COVID-19, for whom surgical intervention is associated with an extremely high risk, needs to be clarified. © 2022, Media Sphera Publishing Group. All rights reserved.

2.
Journal of Hazardous Materials Advances ; : 100159, 2022.
Article in English | ScienceDirect | ID: covidwho-2007714

ABSTRACT

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in a global pandemic starting in 2019 with nearly 500 million confirmed cases as of April 2022. Infection with SARS-CoV-2 is accompanied by shedding of virus in stool, and its presence in wastewater samples has been documented globally. Therefore, monitoring of SARS-CoV-2 in wastewater offers a promising approach to assess the pandemic situation covering pre-symptomatic and asymptomatic cases in areas with limited clinical testing. In this study, the presence of SARS-CoV-2 RNA in wastewater from five wastewater resource recovery facilities (WRRFs), located in two adjacent counties, was investigated and compared with the number of clinical COVID-19 cases during a 2020-2021 outbreak in United States. Statistical correlation analyses of SARS-CoV-2 viral abundance in wastewater and COVID-19 daily vs weekly clinical cases was performed. While a weak correlation on a daily basis was observed, this correlation improved when weekly clinical case data were applied. The viral fecal indicator Pepper Mild Mottle Virus (PMMoV) was furthermore used to assess the effects of normalization and the impact of dilution due to infiltration in the wastewater sheds. Normalization did not improve the correlations with clinical data. However, PMMoV provided important information about infiltration and presence of industrial wastewater discharge in the wastewater sheds. This study showed the utility of WBE to assist in public health responses to COVID-19, emphasizing that routine monitoring of large WRRFs could provide sufficient information for large-scale dynamics.

3.
Heliyon ; 8(7): e09887, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-2004105

ABSTRACT

Galahad™ is a proanthocyanidin complexed with polysaccharides that inactivates viruses and indicates potential for an innovative approach to making protective vaccines. The polysaccharide portion of Galahad™ consists mainly of arabinan and arabinogalactan. In a seven-day toxicity study in rats, it was not toxic even when tested undiluted. Galahad™ inactivated a wide range of DNA and RNA viruses including adenoviruses, corona viruses such as SARS-CoV-2, and influenza viruses. Electron microscopy studies showed that exposure to Galahad™ caused extensive clumping of virions followed by lack of detection of virions after longer periods of exposure. Based on the viral inactivation data, the hypotheses tested is that Galahad™ inactivation of virus can be used to formulate a protective inactivated virus vaccine. To evaluate this hypothesis, infectious influenza A virus (H5N1, Duck/MN/1525/81) with a titer of 105.7 CCID50/0.1 ml was exposed for 10 min to Galahad™. This treatment caused the infectious virus titer to be reduced to below detectable limits. The Galahad™ -inactivated influenza preparation without adjuvant or preservative was given to BALB/c mice using a variety of routes of administration and dosing regimens. The most protective route of administration and dosing regimen was when mice were given the vaccine twice intranasally, the second dose coming 14 days after the primary vaccine dose. All the mice receiving this vaccine regimen survived the virus challenge while only 20% of the mice receiving placebo survived. This suggests that a Galahad™-inactivated influenza virus vaccine can elicit a protective immune response even without the use of an adjuvant. This technology should be investigated further for its potential to make effective human vaccines.

4.
Physiol Rep ; 10(16): e15391, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1994596

ABSTRACT

The acute phase of COVID-19 has been well studied, however with increasing post-acute COVID-19 syndrome, much is unknown about its long-term effects. A common symptom in both the acute and post-acute phases has been fatigue, assessed predominantly qualitatively. Here we present a case study objectively assessing neuromuscular fatiguability in a young male (27 year, 1.85 m, 78 kg) who continues to experience COVID-19 related fatigue and cognitive dysfunction, including other symptoms, 12+ months post-infection. Prior to infection, he was part of a neuromuscular study forming the basis of our pre-COVID-19 results. The study was repeated 12 months post-COVID-19 infection. Muscle strength, endurance, torque steadiness, voluntary activation, twitch properties, electromyography, and compound muscle action potential were obtained and compared pre- and post-COVID-19. All measurements were done using a dorsiflexion dynamometer in which the participant also was asked to produce a one-minute fatiguing maximal voluntary contraction. Muscle strength, voluntary activation, and fatigability (slope of torque) showed no meaningful differences, suggesting intrinsic neuromuscular properties are not affected. However, torque steadiness was impaired three-fold in the post- compared with pre-COVID-19 test. The participant also reported a higher level of perceived exertion subjectively and a continued complaint of fatigue. These findings indicate that muscle fatiguability in post-acute COVID-19 syndrome may not be a limitation of the muscle and its activation, but a perceptual disconnect caused by cognitive impairments relating to physical efforts. This case report suggests the potential value of larger studies designed to assess these features in post-acute COVID-19 syndrome.

5.
BMC Med Inform Decis Mak ; 22(1): 214, 2022 08 12.
Article in English | MEDLINE | ID: covidwho-1993356

ABSTRACT

BACKGROUND: Since the outbreak of COVID-19 pandemic in Rwanda, a vast amount of SARS-COV-2/COVID-19-related data have been collected including COVID-19 testing and hospital routine care data. Unfortunately, those data are fragmented in silos with different data structures or formats and cannot be used to improve understanding of the disease, monitor its progress, and generate evidence to guide prevention measures. The objective of this project is to leverage the artificial intelligence (AI) and data science techniques in harmonizing datasets to support Rwandan government needs in monitoring and predicting the COVID-19 burden, including the hospital admissions and overall infection rates. METHODS: The project will gather the existing data including hospital electronic health records (EHRs), the COVID-19 testing data and will link with longitudinal data from community surveys. The open-source tools from Observational Health Data Sciences and Informatics (OHDSI) will be used to harmonize hospital EHRs through the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The project will also leverage other OHDSI tools for data analytics and network integration, as well as R Studio and Python. The network will include up to 15 health facilities in Rwanda, whose EHR data will be harmonized to OMOP CDM. EXPECTED RESULTS: This study will yield a technical infrastructure where the 15 participating hospitals and health centres will have EHR data in OMOP CDM format on a local Mac Mini ("data node"), together with a set of OHDSI open-source tools. A central server, or portal, will contain a data catalogue of participating sites, as well as the OHDSI tools that are used to define and manage distributed studies. The central server will also integrate the information from the national Covid-19 registry, as well as the results of the community surveys. The ultimate project outcome is the dynamic prediction modelling for COVID-19 pandemic in Rwanda. DISCUSSION: The project is the first on the African continent leveraging AI and implementation of an OMOP CDM based federated data network for data harmonization. Such infrastructure is scalable for other pandemics monitoring, outcomes predictions, and tailored response planning.


Subject(s)
COVID-19 , SARS-CoV-2 , Artificial Intelligence , COVID-19/epidemiology , COVID-19 Testing , Data Science , Humans , Pandemics/prevention & control , Rwanda/epidemiology
7.
Am J Transplant ; 2022 Jul 23.
Article in English | MEDLINE | ID: covidwho-1973539

ABSTRACT

A recent study concluded that SARS-CoV-2 mRNA vaccine responses were improved among transplant patients taking mTOR inhibitors (mTORi). This could have profound implications for vaccine strategies in transplant patients; however, limitations in the study design raise concerns about the conclusions. To address this issue more robustly, in a large cohort with appropriate adjustment for confounders, we conducted various regression- and machine learning-based analyses to compare antibody responses by immunosuppressive agents in a national cohort (n = 1037). MMF was associated with significantly lower odds of positive antibody response (aOR = 0.09 0.130.18 ). Consistent with the recent mTORi study, the odds tended to be higher with mTORi (aOR = 1.00 1.452.13 ); however, importantly, this seemingly protective tendency disappeared (aOR = 0.47 0.731.12 ) after adjusting for MMF. We repeated this comparison by combinations of immunosuppression agents. Compared to MMF + tacrolimus, MMF-free regimens were associated with higher odds of positive antibody response (aOR = 2.39 4.267.92 for mTORi+tacrolimus; 2.34 5.5415.32 for mTORi-only; and 6.78 10.2515.93 for tacrolimus-only), whereas MMF-including regimens were not, regardless of mTORi use (aOR = 0.81 1.542.98 for MMF + mTORi; and 0.81 1.512.87 for MMF-only). We repeated these analyses in an independent cohort (n = 512) and found similar results. Our study demonstrates that the recently reported findings were confounded by MMF, and that mTORi is not independently associated with improved vaccine responses.

8.
Mikrochim Acta ; 189(8): 287, 2022 07 19.
Article in English | MEDLINE | ID: covidwho-1935815

ABSTRACT

A dual recognition biosensor was developed via introducing aptamer strings and molecular imprinting polymer (MIP) for the selective detection of intact SARS-CoV-2 virus based on screen printed carbon electrode (SPCE) modified with nickel-benzene tricarboxylic acid-metal-organic framework (Ni3(BTC)2 MOF) synthesized by in situ growth method, SARS-CoV-2 S protein-specific amino-aptamer and electropolymerization of dopamine (ePDA). The proposed biosensor showed an excellent linear relationship between charge transfer resistance (Rct) and increase in virus concentration in the range 10 to 108 plaque-forming units/mL (PFU/mL) with a low detection limit of 3.3 ± 0.04 PFU/mL and response time of 20 min. Compared with single-element sensors (aptamer or MIP), it showed higher selectivity for  the SARS-CoV-2 virus and facilitated detection in real samples.


Subject(s)
COVID-19 , Molecular Imprinting , COVID-19/diagnosis , Humans , Molecular Imprinting/methods , Polymers/chemistry , SARS-CoV-2 , Spike Glycoprotein, Coronavirus
9.
Am J Transplant ; 2022 Jul 01.
Article in English | MEDLINE | ID: covidwho-1932268

ABSTRACT

The Coronavirus Disease 2019 (COVID-19) pandemic has substantially impacted solid organ transplantation, including temporary inactivation of waitlist candidates with COVID-19 infection. We report two cases of liver transplantation (LT) in individuals with asymptomatic COVID-19 infection. The first patient is a 68-year-old female with decompensated cirrhosis complicated by worsening frailty and sarcopenia. The second patient is a 22-year-old female with acute liver failure likely secondary to drug/toxin exposure. Both patients were treated with COVID-19-directed therapies and neither patient developed symptomatic disease. These cases demonstrate that LT can be safely performed in select patients with asymptomatic COVID-19 infection at the time of transplant.

10.
Am J Transplant ; 2022 Jul 13.
Article in English | MEDLINE | ID: covidwho-1927554

ABSTRACT

The COVID-19 pandemic has influenced organ transplantation decision making. Opinions regarding the utilization of coronavirus disease-2019 (COVID-19) donors are mixed. We hypothesize that COVID-19 infection of deceased solid organ transplant donors does not affect recipient survival. All deceased solid organ transplant donors with COVID-19 testing results from March 15, 2020 to September 30, 2021 were identified in the OPTN database. Donors were matched to recipients and stratified by the COVID-19 test result. Outcomes were assessed between groups. COVID-19 test results were available for 17 694 donors; 150 were positive. A total of 269 organs were transplanted from these donors, including 187 kidneys, 57 livers, 18 hearts, 5 kidney-pancreases, and 2 lungs. The median time from COVID-19 testing to organ recovery was 4 days for positive and 3 days for negative donors. Of these, there were 8 graft failures (3.0%) and 5 deaths (1.9%). Survival of patients receiving grafts from COVID-19-positive donors is equivalent to those receiving grafts from COVID-19-negative donors (30-day patient survival = 99.2% COVID-19 positive; 98.6% COVID-19 negative). Solid organ transplantation using deceased donors with positive COVID-19 results does not negatively affect early patient survival, though little information regarding donor COVID-19 organ involvement is known. While transplantation is feasible, more information regarding COVID-19-positive donor selection is needed.

11.
Am J Transplant ; 2022 Jul 08.
Article in English | MEDLINE | ID: covidwho-1927553

ABSTRACT

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has been associated with a high risk of adverse outcomes in solid organ transplant (SOT) recipients in the pre-vaccination era. In this retrospective cohort study, we examined the incidence and severity of COVID-19 in kidney and liver transplant recipients in Denmark in the post-vaccination era, from December 27, 2020, to December 27, 2021. We included 1428 SOT recipients with 143 cases of first-positive SARS-CoV-2 PCR test. The cumulative incidence of first-positive SARS-CoV-2 PCR test 1 year after initiation of vaccination was 10.4% (95% CI: 8.8-12.0), and the incidence was higher in kidney than in liver transplant recipients (11.6% [95% CI: 9.4-13.8] vs. 7.4% [95% CI: 5.1-9.8], p = .009). After the first-positive SARS-CoV-2 PCR test, the hospitalization rate was 31.5% (95% CI: 23.9-39.1), and 30-day all-cause mortality was 3.7% (95% CI: 0.5-6.8). Hospitalization was lower in vaccinated than in unvaccinated SOT recipients (26.4% [95% CI: 18.1-34.6] vs. 48.5% [95% CI: 31.4-65.5], p = .011), as was mortality (1.8% [95% CI: 0.0-4.3] vs. 9.1% [95% CI: 0.0-18.9], p = .047). In conclusion, SOT recipients remain at high risk of adverse outcomes after SARS-CoV-2 infections, with a lower risk observed in vaccinated than in unvaccinated SOT recipients.

12.
Advances in Applied Microbiology ; 2022.
Article in English | ScienceDirect | ID: covidwho-1926132

ABSTRACT

The term Gain-of-Function (GoF) describes the gain of new functions by organisms through genetic changes, which can naturally occur or by experimental genetic modifications. Gain-of-Function research on viruses is enhancing transmissibility, virus replication, virulence, host range, immune evasion or drug and vaccine resistance to get insights into the viral mechanisms, to create and analyze animal models, to accelerate drug and vaccine development and to improve pandemic preparedness. A subset is the GoF research of concern (GOFROC) on enhanced potentially pandemic pathogens (ePPPs) that could be harmful for humans. A related issue is the military use of research as dual-use research of concern (DURC). Influenza and coronaviruses are main research targets, because they cause pandemics by airborne infections. Two studies on avian influenza viruses initiated a global debate and a temporary GoF pause in the United States which ended with a new regulatory framework in 2017. In the European Union and China, GoF and DURC are mainly covered by the legislation for laboratory safety and genetically modified organisms. After the coronavirus outbreaks, the GoF research made significant advances, including analyses of modified MERS-like and SARS-like viruses and the creation of synthetic SARS-CoV-2 viruses as a platform to generate mutations. The GoF research on viruses will still play an important role in future, but the need to clarify the differences and overlaps between GoF research, GOFROC and DURC and the need for specialized oversight authorities are still debated.

13.
Am J Transplant ; 2022 Jul 08.
Article in English | MEDLINE | ID: covidwho-1922817

ABSTRACT

The risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization and death, and the effects of SARS-CoV-2 vaccines in solid organ transplant recipients (SOTRs) is still debated. We performed a nationwide, population-based, matched cohort study, including all Danish SOTRs (n = 5184) and a matched cohort from the general population (n = 41 472). Cox regression analyses were used to calculate incidence rate ratios (IRRs). SOTRs had a slightly increased risk of SARS-CoV-2 infection and were vaccinated earlier than the general population. The overall risk of hospital contact with COVID-19, severe COVID-19, need for assisted respiration, and hospitalization followed by death was substantially higher in SOTRs (IRR: 32.8 95%CI [29.0-37.0], 9.2 [6.7-12.7], 12.5 [7.6-20.8], 12.4 [7.9-12.7]). The risk of hospitalization and death after SARS-CoV-2 infection decreased substantially in SOTRs after the emergence of the Omicron variant (IRR: 0.45 [0.37-0.56], 0.17 [0.09-0.30]). Three vaccinations reduced the risk of SARS-CoV-2 infection only marginally compared to two vaccinations, but SOTRs with three vaccinations had a lower risk of death (IRR: 022 [0.16-0.35]). We conclude that SOTRs have a risk of SARS-CoV-2 infection comparable to the general population, but substantially increased the risk of hospitalization and death following SARS-CoV-2 infection. A third vaccination only reduces the risk of SARS-CoV2 infection marginally, but SOTRs vaccinated 3 times have reduced mortality.

14.
Human Evolution ; 36(1-2):139-144, 2021.
Article in English | Scopus | ID: covidwho-1924736

ABSTRACT

It is striking that East Asian, South East Asian and South Pacific Populations appear relatively unscathed by the second and subsequent waves of the SARS-CoV-2 pandemic compared to the rest of the world. This is more so with the more infectious G614 mutation of COVID-19. Adherence to social distancing measures and face protection do not explain the almost 30-fold difference in infection incidence between Asian and European/ American populations. The populations in the Indian Subcontinent are an exception, as infections rates were elevated compared to other Asian countries. Differences in immune responses between European and African populations have been alluded to because of archaic introgression of immune-related Neanderthal genes in the European genome. As opposed to the European genome, the Asian genome has a higher introgression of the Neanderthal’s sister species’ genes, the Denisovan genes, which are more commonly found in East and South East Asia and the South Pacific populations. Contrastingly the Denisonvan genes are scantily found in the populations of the Indian Subcontinent. Lockdown in China and bordering nations, led to significant reductions in atmospheric pollution, which itself significantly attenuates pulmonary immunity. Following lockdown in January the G614 variant emerged in China. With improved immunity following lockdown, the Denisovan immunity-related gene may have been allowed to be expressed more effectively, protecting Asian populations against the more infectious G614 variant of SARS-CoV-2 during the subsequent waves of the pandemic. © 2021 Angelo Pontecorboli Editore - EDK. All rights reserved.

15.
Drugs of the Future ; 47(2):151-154, 2022.
Article in English | Scopus | ID: covidwho-1910461

ABSTRACT

The European Society of Gene and Cell Therapy (ESGCT) held its 28th annual congress in virtual format, bringing together experts and product specialists in the field of gene therapy, cell therapy and genetic vaccines. © 2022 Prous Science. All rights reserved.

16.
ChemElectroChem ; 9(12), 2022.
Article in English | ProQuest Central | ID: covidwho-1905823

ABSTRACT

Environmental problems of great complexity arise from the enormous number of toxic substances that are generated by anthropogenic activities. Seemingly, society encounters new issues every day thus these problems seem to be endless. Now in the face of the COVID‐19 pandemic and the SARS‐CoV‐2 crisis, a large number of emerging treatment compounds generated by pharmaceutical companies worldwide makes future issues even more treacherous. For this reason, there is an increasing need to detect and treat emerging compounds to prevent them from becoming persistent pollutants. This review describes the advances in the use of electrochemical sensors with modified carbon‐based electrodes among other issues, to determine antibiotics, anti‐inflammatories and antidepressants levels in the environment. It further explores technologies suggested for cleaning wastewater polluted by pharmaceutical products using biological or advanced oxidation processes including photolysis, photocatalysis, microwave heating, ultrasound, Fenton, electro‐Fenton, photoelectro‐Fenton and various combined treatments.We, the authors, dedicate this report, with love, to all the people afflicted by COVID-19 during the pandemic arising from SARS-CoV-2. In particular, we wish to honor the medical people who have and continue to help affected patients, and the medical researchers who generate the medicines and vaccines for all of us.

17.
J Surg Case Rep ; 2022(6): rjac289, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1908854

ABSTRACT

A multiparous pregnant patient was admitted to the intensive care unit in her third trimester of pregnancy for prone positioning mechanical ventilation after developing SARS-CoV2 (COVID-19)-related acute respiratory distress syndrome. Repositioning in left lateral tilt was followed by uterine contractions and cardiotocography alterations. Preterm caesarean section was performed based on persistent foetal tachycardia and suspected foetal distress, followed by a per-operative diagnosis of uterine levotorsion. This case report is the first to explore a potential causal link between prolonged prone positioning in late pregnancy and postural gravid uterine torsion and highlights the need for appropriate foetal monitoring during prone positioning mechanical ventilation support.

18.
Handbook of research on updating and innovating health professions education: Post-pandemic perspectives ; : 265-297, 2022.
Article in English | APA PsycInfo | ID: covidwho-1903603

ABSTRACT

The rapid transition to distance learning in response to the unexpected SARS-CoV-2/COVID-19 pandemic led to disruption of clinical skills development, which are typically conducted face-to-face. Consequently, faculty adapted their courses, using a multitude of active learning modalities, to meet student learning objectives in the didactic and experiential settings. Strategies and considerations to implement innovative delivery methods and address potential challenges are elucidated. Furthermore, integration of a layered learning approach may allow for more broad perspectives and allow additional interactions and feedback, which is especially necessary in the virtual environment. (PsycInfo Database Record (c) 2022 APA, all rights reserved)

19.
Am J Transplant ; 2022 Jun 22.
Article in English | MEDLINE | ID: covidwho-1901570

ABSTRACT

Coronavirus disease-19 has had a marked impact on the transplant population and processes of care for transplant centers and organ allocation. Several single-center studies have reported successful utilization of deceased donors with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests. Our aims were to characterize testing, organ utilization, and transplant outcomes with donor SARS-CoV-2 status in the United States. We used Scientific Registry of Transplant Recipients data from March 12, 2020 to August 31, 2021 including a custom file with SARS-CoV-2 testing data. There were 35 347 donor specimen SARS-CoV-2 tests, 77.5% upper respiratory samples, 94.6% polymerase chain reaction tests, and 1.2% SARS-CoV-2-positive tests. Donor age, gender, history of hypertension, and diabetes were similar by SARS-CoV-2 status, while positive SARS-CoV-2 donors were more likely African-American, Hispanic, and donors after cardiac death (p-values <.01). Recipient demographic characteristics were similar by donor SARS CoV-2 status. Adjusted donor kidney discard (odds ratio = 2.08, 95% confidence interval [CI] 1.66-2.61) was higher for SARS-CoV-2-positive donors while donor liver (odds ratio = 0.44, 95% CI 0.33-0.60) and heart recovery (odds ratio = 0.44, 95% CI 0.31-0.63) were significantly reduced. Overall post-transplant graft survival for kidney, liver, and heart recipients was comparable by donor SARS-CoV-2 status. Cumulatively, there has been significantly lower utilization of SARS-CoV-2 donors with no evidence of reduced recipient graft survival with variations in practice over time.

20.
Am J Transplant ; 2022 Jun 17.
Article in English | MEDLINE | ID: covidwho-1895939

ABSTRACT

The cilgavimab-tixagevimab combination retains a partial in vitro neutralizing activity against the current SARS-CoV-2 variants of concern (omicron BA.1, BA.1.1, and BA.2). Here, we examined whether preexposure prophylaxis with cilgavimab-tixagevimab can effectively protect kidney transplant recipients (KTRs) against the omicron variant. Of the 416 KTRs who received intramuscular prophylactic injections of 150 mg tixagevimab and 150 mg cilgavimab, 39 (9.4%) developed COVID-19. With the exception of one case, all patients were symptomatic. Hospitalization and admission to an intensive care unit were required for 14 (35.9%) and three patients (7.7%), respectively. Two KTRs died of COVID-19-related acute respiratory distress syndrome. SARS-CoV-2 sequencing was carried out in 15 cases (BA.1, n = 5; BA.1.1, n = 9; BA.2, n = 1). Viral neutralizing activity of the serum against the BA.1 variant was negative in the 12 tested patients, suggesting that this prophylactic strategy does not provide sufficient protection against this variant of concern. In summary, preexposure prophylaxis with cilgavimab-tixagevimab at the dose of 150 mg of each antibody does not adequately protect KTRs against omicron. Further clarification of the optimal dosing can assist in our understanding of how best to harness its protective potential.

SELECTION OF CITATIONS
SEARCH DETAIL